MIRA INFORM REPORT

 

 

Report Date :

27.04.2012

 

IDENTIFICATION DETAILS

 

Name :

SIGMATEC PHARMACEUTICAL INDUSTRIES SAE

 

 

Registered Office :

6th Industrial Zone, Plot B/1, Giza, 6th of October City

 

 

Country :

Egypt

 

 

Year of Establishment :

 2007

 

 

Legal Form :

Egyptian Joint Stock Company

 

 

Line of Business :

Manufacture of pharmaceutical capsules and vials.

 

 

No. of Employees :

2,500

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

Usually Correct 

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Egypt

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 


SUMMARY

 

Company Name                         : SIGMATEC PHARMACEUTICAL INDUSTRIES SAE

Country of Origin                                    : Egypt

Legal Form                                            : Egyptian Joint Stock Company

Registration Date                                   : 2007

Issued Capital                                        : £E 50,000,000

Paid up Capital                                      : £E 50,000,000

Total Workforce                                     : 2,500

Activities                                               : Manufacture of pharmaceutical capsules and vials.

Financial Condition                                 : Undetermined

Payments                                             : Nothing detrimental uncovered

Person Interviewed                                 : Mohmoud Al Najjar, Administration Secretary

 

 

 


COMPANY NAME

 

SIGMATEC PHARMACEUTICAL INDUSTRIES SAE

 

 

company ADDRESS

 

Registered & Physical Address

Location            : 6th Industrial Zone, Plot B/1, Giza

Town                 : 6th of October City

Country             : Egypt

Telephone         : (20-2) 38278740 / 38278741 / 38278742 / 38278744

Facsimile          : (20-2) 38278760 / 38278760

Mobile               : (20-111) 6966660 / 6114433 / 66 / 77 / 88 / 99

Email                : m-elenna@sigm-corp.net / loui@sigma-corp.net / elnajjar@sigmapharm.net

 

Premises

Subject operates from a large suite of offices and a factory that are rented and located in the Industrial Area of 6th of October City.

 

 

KEY PRINCIPALS

 

     Name                                                                                              Position

 

·       Dr Sayad El Badawi                                                                          Chairman

 

·       Dr Mohsen El Enaa                                                                           Vice Chairman

 

·       Dr Atef Deraaz                                                                                  Director

 

·       Dr Ahmed Habib                                                                                Director

 

·       Dr Loui El Halabi                                                                               Export Manager

 

·       Dr Mohamed Khattab                                                             Marketing Manager

 

·       Wahid Helmy                                                                                    Finance Manager

 

·       Hamdy Hussain                                                                                Accounts Manager

 

·       Mohmoud Al Najjar                                                                            Administration Secretary

 

 


LEGAL FORM & OWNERS

 

Date of Establishment  : 2007

 

Legal Form                  : Egyptian Joint Stock Company

 

Issued Capital              : £E 50,000,000

 

Paid up Capital            : £E 50,000,000

 

Name of Shareholder (s)                                             

 

·       Sigma Group

Egypt

 

·       Dr Sayad El Badawi                                                                         

 

·       Dr Mohsen El Enaa                                                                          

 

·       Dr Atef Deraaz                                                                                 

 

·       Dr Ahmed Habib

 

 

AFFILIATED COMPANIES

 

·       Sigma Pharmaceuticals Industries

Quesna

 

 

OPERATIONS

 

Activities: Engaged in the manufacture of pharmaceutical capsules and vials.

 

                 Subject is ISO 9001 accredited.

 

Import Countries: Europe and the Far East.

 

Subject has a workforce of approximately 2,500 employees.

 

 

FINANCIAL DATA

 

Companies registered in Egypt are not legally required to make their accounts public and no financial information was released by the company or submitted by outside sources.

 

 

BANKERS

 

·       Export Development Bank of Egypt

     Plot 3/1

4th Industrial Region

6th of October City

Tel: (20-11) 38330577 / 38330599

Fax: (20-11) 38330570 / 38330551

 

 

PAYMENT HISTORY

 

No complaints regarding subject’s payments have been reported.

 

 

GENERAL COMMENTS

 

During the course of this investigation nothing detrimental was uncovered regarding subject’s operating history or the manner in which payments are fulfilled. As such the company is considered to be a fair trade risk.


 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.52.57

UK Pound

1

Rs.85.03

Euro

1

Rs.69.56

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.